Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Latest From Ramsey Baghdadi
The rebate rule is dead, but we should pay tribute to the failed endeavor.
Broad bipartisan support and billions in projected savings mean that bill may finally pass. But whether it will work as intended to improve generic access to market remains as questionable as ever.
There are rumblings a drug importation proposal is coming, but there are no signs that the HHS/FDA working group has been active in the year since it was created.
For all the rumors of political infighting, the two cornerstones of the Trump administration’s blueprint on drug pricing are in the final phase for review.
As final decision looms, initial move to hold off on DRG but increase payment for CAR-T therapies shows CMS taking a slow and steady approach to paying for the products.